DNA

Part:BBa_K2100024:Experience

Designed by: Kathleen Brandes   Group: iGEM16_MIT   (2016-10-14)


This experience page is provided so that any user may enter their experience using this part.
Please enter how you used this part and how it worked out.

Applications of BBa_K2100024

This is the promoter that is repressed by the TAL14 repressor. In testing the TAL14 repressor, we used this promoter cascaded with eYFP as an indicator as to how much repression is caused by the actual repressor when activated. Here are the experiments we did using the TAL14 repressor and its partnering promoter.

We used our repressor to build multiple constructs including:
- pTRE:TAL14 to characterize its base level functionality
- pERE3:TALER14, pERE5:TALER14 and pERE6:TALER14 to characterize the cascade of our promoters with the TAL14 repressors


Cascade of pTRE:TAL14



We characterized the repressor TAL14 by creating a plasmid TRE:TAL14, containing TAL14 under the control of a doxycycline inducible promoter, TRE. This allowed for us to modulate the repressor expression by varying the concentrations of doxycycline added. We also created a repressible promoter controlling the expression of a fluorescent protein. This plasmid allowed for us to measure the repression occurring.


MIT_repressor_expt.png

In order for us to analyze the level of repression, we need to see sustained presence. Upon increasing the concentration of doxycycline, we were unable to see that sustained presence of the repressors. From the results of testing TAL14 below, it can be seen that although there is activation early on, the production of repressor falls at 500 nM. This could possible be due to errors in doxycycline dilutions at 500 nM and above.

[image here]



Cascade of pERExN:TAL14



We experimented with our promoter pENTR pERExN cloned with repressors (pENTR TALER14) to test the functionality of the promoters in a cascade. These experiments entailed multiple plasmids to be activated: pERExN:TALER14 (500ng), pTALER14:eYFP (170ng), hEF1a:mKate (170ng), hEF1a:Gal4VP16 (170ng), which is approximately a 3:1:1:1 ratio of plasmids.

778px-T--MIT--khb_repressors_for_parts.jpeg

(1) Estrogen diffuses into the cell and binds with the estrogen receptor. (2) Estrogen receptors will homodimerize with one another forming an activation complex. (3) Estrogen receptor will bind to our synthetic promoter (4) Production of repressor protein (5) Repressor binds to binding sites upstream of an eYFP reporter (6) Transactivator Gal4-VP16 is constitutively produced (7) Gal4-VP16 binds to sites on pRep (8) eYFP is produced as readout depending upon how active repressors are (9) Constituively active transfection marker hEF1a:mKate allows us to bin and analyze the data.

Our estrogen sensitive promoters respond to increases in E2 levels by producing more of the repressor. The repressors then bind to binding sites in a promoter upstream of fluorescent reporter eYFP. The constitutively active trans-activator Gal4-VP16 sets a large basal eYFP expression when there is no repressor, so that a measurable drop in signal can be observed when repressors are active. Constituvely active hEF1a mKate serves as a transfection marker by which we bin our data.



Experiment with pERExN:TAL14 in ISH:

The first cell line in which we deployed our genetic circuit was ISH, the endometrial epithelial cell line. We had expected eYFP expression to decrease after induction of our promoter - repressor cascades with E2.
T--MIT--khb_e3repish.jpeg
This is pERE3:TAL14 in ISH.
T--MIT--khb_e5repish.jpeg
This is pERE5:TAL14 in ISH.
T--MIT--khb_e6repish.jpeg
This is pERE6:TAL14 in ISH.
Blue contours represent the cell population that was left uninduced, green contours represent the cell population that was induced with 5 nM E2. However, we were unable to resolve a clear fold difference between the uninduced and induced population in any of the pERExN and TAL14 cascades. This is probably an artifact of poor transfection in the ISH cell line for this experiment (less than 2 percent transfected after cationic lipid transfection), which leads to erratic jumps in the data after binning by constitutive marker. In the future, we may want to try other modes of transfection for ISH to improve the transfection efficiency.

Experiment with pERExN:TAL14 in MCF7:

We next proceeded to deploy this experiment in MCF7. We hypothesized that we were unable to resolve a clear fold difference in our pERExN - repressor cascades transfected into ISH because of the limited functionality of our promoters in the ISH cell line. So, we proceeded to transfect our cells into the MCF7 cell line where we had observed up to a 11 fold difference in the activity of some of our promoters.
T--MIT--khb_e3repmc.jpeg
This is the cascade of pERE3:TAL14 in MCF7.
T--MIT--khb_thesc_pic_test.jpeg
This is the cascade of pERE5:TAL14 in MCF7.
T--MIT--khb_e6repmc.jpeg
This is the cascade of pERE6:TAL14 in MCF7.
Blue contours represent the cell population that was left uninduced, green contours represent the cell population that was induced with 5 nM E2.
Similarly, we had expected eYFP expression to decrease after induction of our promoter - repressor cascades with E2. However, we were still unable to resolve a clear fold difference between the uninduced and induced population in any of the pERExN and TAL14 cascades due to a poor transfection efficiency in the experiments.

Overall, we were still unable to resolve a clear fold difference between the uninduced and induced population in any of the pERExN or TRE and TAL14 cascades. Given more time, we would like to explore whether transfecting our entire circuit on one plasmid instead of five separate plasmids would lead to better results.

User Reviews

UNIQc6b6978f983d4bc8-partinfo-00000000-QINU UNIQc6b6978f983d4bc8-partinfo-00000001-QINU